Teva Pharmaceutical Industries LimitedTEVANYSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -5.12% | +1.89% | +0.29% | +3.44% | +11.40% |
| Gross Profit Growth | -12.25% | +5.99% | +3.85% | +7.26% | +25.28% |
| EBITDA Growth | -23.40% | +1287.27% | +167.07% | +433.33% | -45.61% |
| Operating Income Growth | -103.84% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | -146.87% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | -146.34% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | -146.34% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.07% | +1.34% | +1.24% | +1.24% | +1.41% |
| Weighted Average Shares Diluted Growth | -0.35% | +3.21% | +2.47% | +2.74% | +3.53% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -51.44% | +0.00% | +120.39% | -46.75% | +101.39% |
| Free Cash Flow Growth | -58.12% | +0.00% | +2083.33% | -57.25% | +127.80% |
| Receivables Growth | -10.24% | -2.08% | -5.36% | +10.05% | +21.25% |
| Inventory Growth | -25.22% | -17.78% | -10.95% | -16.06% | +5.72% |
| Asset Growth | -9.55% | -10.19% | -2.92% | -4.55% | +3.62% |
| Book Value per Share Growth | -29.18% | -15.09% | +6.05% | +18.08% | +45.17% |
| Debt Growth | -10.29% | -15.04% | -7.39% | -11.33% | -3.86% |
| R&D Expense Growth | +15.81% | +2.07% | -9.29% | +6.67% | -1.48% |
| SG&A Expenses Growth | +5.54% | +3.72% | +2.13% | +5.30% | +17.65% |